Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 – February 29-March 1, 2024 / West Palm Beach, FL
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase 3 evolutionRMS1 and 2 Trials
Montalban | Oral #LB1.4
Self-Reported Adherence and Safety of Cladribine Tablets in Patients with Relapsing Multiple Sclerosis After Suboptimal Response to Prior Oral or Infusion Disease-Modifying Therapy: 6-Month Interim Analysis From the US-Based Phase 4 MASTER-2 Study
Bass | Poster #493
Characterizing Disability Accumulation with Patient-Reported Outcomes and Clinical Outcomes in Patients with Multiple Sclerosis in the MS-LINK Outcomes Study Cohort
English| Poster #494
Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis 2023 Post-Approval Safety Update
Giovannoni | Poster #475
Pregnancy and Infant Outcomes from an Ongoing Worldwide Enhanced Pharmacovigilance Program of Cladribine Tablets: 6-Year Results From MAPLE-MS
Hellwig | Poster #508
Clinical Efficacy of Cladribine Tablets in Patients with Highly Active Relapsing Multiple Sclerosis: 36-Month Interim Results from the Extension Trial to the MAGNIFY-MS Study
Hodgkinson | Poster #073
Effectiveness, Self-Reported Adherence, and Safety of Cladribine Tablets in Patients with Relapsing Multiple Sclerosis After Suboptimal Response to Prior Injectable Disease-Modifying Therapy: 12-Month Interim Analysis From the US-Based Phase 4 CLICK-MS Study
Katz | Poster #495
Comparative Assessment of Switching Outcomes for Patients with Multiple Sclerosis Receiving Cladribine Tablets vs Fingolimod, Dimethyl fumarate, and Teriflunomide
Lobo | Poster #488
Real-World Outcomes of People with Relapsing Multiple Sclerosis Switching from Natalizumab or Ocrelizumab to Cladribine Tablets
Okuda | Poster #491
Real-World Outcomes with Cladribine Tablets Across Race and Ethnicity of People with Relapsing Multiple Sclerosis
Okuda | Poster #492
Cladribine Tablets After Treatment with Natalizumab (CLADRINA) Trial – Clinical Analysis
Sguigna | Poster #481
Treatment Persistence of Cladribine Tablets Versus Other Oral Disease-Modifying Treatments for Multiple Sclerosis: Results from Danish, Norwegian, and Swedish Registries
Spelman | Poster #473
Improved Cognitive Processing Speed in Patients Treated with Cladribine Tablets for Multiple Sclerosis: MAGNIFY-MS 2-Year Findings
Vermersh | Poster #070
Year 5 After Initiation of Treatment with Cladribine Tablets: Analysis of Longitudinal Prescription Data of People with Multiple Sclerosis in Germany
von der Maßen | Poster #474
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: